AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,783,300 | +16.5% | 2,778,232 | +20.3% | 0.00% | +50.0% |
| Q2 2023 | $29,008,838 | -40.7% | 2,309,621 | -47.7% | 0.00% | 0.0% |
| Q1 2023 | $48,956,538 | +60.9% | 4,414,476 | +77.2% | 0.00% | -33.3% |
| Q4 2022 | $30,423,022 | +4.3% | 2,491,648 | -10.8% | 0.00% | 0.0% |
| Q3 2022 | $29,170,000 | +32.5% | 2,794,068 | +36.3% | 0.00% | +50.0% |
| Q2 2022 | $22,013,000 | +35.8% | 2,049,617 | +19.8% | 0.00% | +100.0% |
| Q1 2022 | $16,204,000 | -12.3% | 1,711,089 | +7.0% | 0.00% | 0.0% |
| Q4 2021 | $18,478,000 | +48.4% | 1,599,832 | +22.7% | 0.00% | 0.0% |
| Q3 2021 | $12,454,000 | -0.9% | 1,304,132 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $12,572,000 | +129.0% | 1,304,132 | +134.6% | 0.00% | – |
| Q1 2021 | $5,491,000 | -93.6% | 555,812 | -85.0% | 0.00% | -100.0% |
| Q4 2020 | $85,525,000 | +37.9% | 3,703,955 | -15.7% | 0.01% | +33.3% |
| Q3 2020 | $62,031,000 | -48.2% | 4,393,188 | -44.7% | 0.01% | -53.8% |
| Q2 2020 | $119,860,000 | +60.8% | 7,948,271 | -1.5% | 0.01% | +30.0% |
| Q1 2020 | $74,546,000 | +318.8% | 8,067,808 | +341.4% | 0.01% | +400.0% |
| Q4 2019 | $17,802,000 | -20.9% | 1,827,687 | -34.9% | 0.00% | -33.3% |
| Q3 2019 | $22,505,000 | -74.1% | 2,806,034 | -59.7% | 0.00% | -70.0% |
| Q2 2019 | $86,932,000 | -57.9% | 6,965,715 | -54.1% | 0.01% | -60.0% |
| Q1 2019 | $206,446,000 | +20.1% | 15,179,860 | -15.4% | 0.02% | +4.2% |
| Q4 2018 | $171,900,000 | +5.6% | 17,943,523 | +33.3% | 0.02% | +33.3% |
| Q3 2018 | $162,777,000 | -22.7% | 13,463,780 | -0.1% | 0.02% | -25.0% |
| Q2 2018 | $210,468,000 | +3.8% | 13,474,295 | -0.0% | 0.02% | 0.0% |
| Q1 2018 | $202,715,000 | -21.7% | 13,478,355 | -25.1% | 0.02% | -20.0% |
| Q4 2017 | $258,782,000 | -11.2% | 17,983,531 | -6.9% | 0.03% | -14.3% |
| Q3 2017 | $291,283,000 | +34.9% | 19,315,817 | -9.9% | 0.04% | +29.6% |
| Q2 2017 | $215,876,000 | +46.0% | 21,437,508 | +3.4% | 0.03% | +42.1% |
| Q1 2017 | $147,822,000 | +39.3% | 20,732,355 | -2.9% | 0.02% | +35.7% |
| Q4 2016 | $106,103,000 | -32.8% | 21,348,929 | +0.1% | 0.01% | -33.3% |
| Q3 2016 | $157,774,000 | +51.9% | 21,320,863 | +12.1% | 0.02% | +50.0% |
| Q2 2016 | $103,865,000 | -34.4% | 19,023,053 | +1.6% | 0.01% | -36.4% |
| Q1 2016 | $158,211,000 | -12.9% | 18,723,103 | -0.1% | 0.02% | -8.3% |
| Q4 2015 | $181,729,000 | -12.2% | 18,734,915 | +26.6% | 0.02% | -17.2% |
| Q3 2015 | $206,982,000 | +11.7% | 14,794,969 | +12.9% | 0.03% | +20.8% |
| Q2 2015 | $185,370,000 | +2930.4% | 13,100,348 | +2230.2% | 0.02% | +2300.0% |
| Q1 2015 | $6,117,000 | +30.8% | 562,204 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $4,678,000 | +39.9% | 562,204 | 0.0% | 0.00% | – |
| Q3 2014 | $3,345,000 | +78.1% | 562,204 | 0.0% | 0.00% | – |
| Q2 2014 | $1,878,000 | +61.3% | 562,204 | 0.0% | 0.00% | – |
| Q1 2014 | $1,164,000 | -11.9% | 562,204 | 0.0% | 0.00% | – |
| Q4 2013 | $1,321,000 | -27.2% | 562,204 | -28.1% | 0.00% | – |
| Q3 2013 | $1,815,000 | -38.7% | 782,383 | -38.5% | 0.00% | – |
| Q2 2013 | $2,962,000 | – | 1,271,322 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |